Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AryoTrust versus Herceptin non-inferiority trial in HER2-positive breast cancer
IRCT201606226135N7Phase 3Completed
- Sponsor
- AryoGen Biopharma
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of trastuzumab in breast cancer (2 arms), sponsored by AryoGen Biopharma. Primary endpoint: Pathologic complete response. Started Jul 2016; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT201606226135N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201606226135N7.